IXICO to provide specialist MR and PET imaging services in Phase II Huntington’s disease clinical trial
IXICO today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term.
IXICO will provide its technology enabled imaging services in a Phase II clinical trial of a novel therapeutic to treat people with Huntington’s disease. As part of the study, IXICO will use its TrialTrackerTM digital platform and scientific services to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America. This data will be analysed using IXICO’s proprietary image analysis workflows and algorithms to evaluate patient eligibility, monitor patient safety and quantify drug effects.